Inogen (INGN) Sets New 1-Year High and Low at $189.76

Shares of Inogen Inc (NASDAQ:INGN) hit a new 52-week high and low during trading on Monday . The stock traded as low as $189.76 and last traded at $180.48, with a volume of 5304 shares. The stock had previously closed at $188.05.

Several analysts recently commented on INGN shares. BidaskClub raised Inogen from a “sell” rating to a “hold” rating in a report on Wednesday, January 24th. Zacks Investment Research raised Inogen from a “hold” rating to a “buy” rating and set a $132.00 price objective for the company in a report on Tuesday, February 6th. Piper Jaffray Companies raised Inogen from a “neutral” rating to an “overweight” rating in a report on Tuesday, February 20th. Finally, Needham & Company LLC lifted their price objective on Inogen from $125.00 to $150.00 and gave the stock a “strong-buy” rating in a report on Wednesday, February 28th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and three have assigned a strong buy rating to the company’s stock. Inogen presently has an average rating of “Buy” and an average price target of $178.00.

The firm has a market capitalization of $3.76 billion, a P/E ratio of 131.61, a price-to-earnings-growth ratio of 4.48 and a beta of 1.01.

Inogen (NASDAQ:INGN) last released its earnings results on Monday, April 30th. The medical technology company reported $0.48 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.29 by $0.19. The company had revenue of $79.05 million for the quarter, compared to the consensus estimate of $63.86 million. Inogen had a return on equity of 14.81% and a net margin of 9.36%. Inogen’s quarterly revenue was up 50.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.27 earnings per share. research analysts anticipate that Inogen Inc will post 1.76 EPS for the current year.

In related news, Director Loren L. Mcfarland sold 2,125 shares of Inogen stock in a transaction on Friday, May 11th. The stock was sold at an average price of $181.44, for a total transaction of $385,560.00. Following the transaction, the director now directly owns 3,114 shares in the company, valued at $565,004.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Heath Lukatch sold 2,500 shares of Inogen stock in a transaction on Thursday, March 1st. The shares were sold at an average price of $119.15, for a total value of $297,875.00. Following the transaction, the director now owns 2,500 shares in the company, valued at $297,875. The disclosure for this sale can be found here. Insiders have sold 40,956 shares of company stock worth $5,724,846 over the last quarter. 5.29% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its position in Inogen by 4.8% during the first quarter. BlackRock Inc. now owns 2,418,048 shares of the medical technology company’s stock valued at $297,032,000 after purchasing an additional 111,514 shares in the last quarter. Brown Capital Management LLC lifted its position in Inogen by 1.8% during the fourth quarter. Brown Capital Management LLC now owns 2,260,706 shares of the medical technology company’s stock valued at $269,205,000 after purchasing an additional 40,994 shares in the last quarter. Rockefeller Financial Services Inc. lifted its position in Inogen by 0.9% during the fourth quarter. Rockefeller Financial Services Inc. now owns 301,499 shares of the medical technology company’s stock valued at $35,903,000 after purchasing an additional 2,729 shares in the last quarter. Rockefeller Capital Management L.P. purchased a new position in Inogen during the first quarter valued at $36,612,000. Finally, Wells Fargo & Company MN lifted its position in Inogen by 7.9% during the first quarter. Wells Fargo & Company MN now owns 297,745 shares of the medical technology company’s stock valued at $36,575,000 after purchasing an additional 21,714 shares in the last quarter. Institutional investors own 99.23% of the company’s stock.

About Inogen

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply